MedTrace Logo

Bio-CAR-T BS Study

NCT05366569 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2026-04-30

No results posted yet for this study

Summary

The aim of this Study is the evaluation of post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion and persistence in patients with DLBCL, PMBCL and ALL undergoing CAR-T therapy; and the feasibility and efficacy of the treatment in the real life practice.

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Acute Lymphoblastic Leukemia (ALL)

Sponsors & Collaborators

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366569 on ClinicalTrials.gov